Publication Name	World Journal of Hepatology
Manuscript ID	3235
Country	United States

Received	2013-04-16 07:59
Peer-Review Started	2013-04-16 10:36
To Make the First Decision	2013-05-14 18:45
Return for Revision	2013-05-17 10:46
Revised	2013-06-02 05:11
Second Decision	2013-06-09 13:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-10 04:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-22 15:25
Publish the Manuscript Online	2013-07-25 09:10

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Adnan Muhammad, Manish Dhamija, Gitanjali Vidyarthi, Donald Amodeo, William Boyd, Branko Miladinovic and Ambuj Kumar
Funding Agency and Grant Number
Corresponding Author	Adnan Muhammad, MD, Department of Gastroenterology, University of South Florida, 12901 Bruce B. Downs Blvd, Tampa, FL 33620, United States. adnan_muhd@hotmail
Key Words	Hepatocellular carcinoma; Transarterial chemoembolization; Sorafenib; Survival; Adverse events
Core Tip	The incidence of hepatocellular carcinoma (HCC) is increasing and there is a need for better treatment modalities. Transarterial chemoembolization (TACE) and sorafenib are the main course of treatment for unresectable HCC. However there is an emphasis to combine them to improve survival. There is very limited data available to compare the effectiveness of TACE alone vs combination with sorafenib. Our results showed equal efficacy for both treatment arms without compromising adverse events. Child-Turcotte-Pugh classification and Barcelona Clinic Liver Cancer staging were significant predictors of survival. This study is the first reported in the literature comparing the outcome when treated with TACE alone vs TACE + sorafenib in United States patients.
Publish Date	2013-07-25 09:10
Citation	Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371
URL	http://www.wjgnet.com/1948-5182/full/v5/i7/364.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i7.364

Full Article (PDF)	WJH-5-364.pdf
Manuscript File	3235-Review.doc
Answering Reviewers	3235-Answering reviewers.pdf
Copyright License Agreement	3235-Copyright assignment.pdf
Peer-review Report	3235-Peer reviews.pdf
Scientific Editor Work List	3235-Scientific editor work list.doc